// App-Quantinova.ai

PB/CO15 : Increased Doses of Low-molecular-weight Heparin in Hospitalized Patients with Covid-19

Researchers

Presenter

  • I. Martinelli

Principal Investigators

  • A. Ciavarella

  • M. Abbattista

  • S. Aliberti

  • V. De Zan

  • C. Folli

  • M. Panigada

  • A. Gori

  • A. Artoni

  • A.M. Ierardi

  • G. Carrafiello

  • V. Monzani

  • G. Grasselli

  • F. Blasi

  • F. Peyvandi

Medical Centers

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy

  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy

  • Universit degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy

  • Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Department of Medicine - Acute Medical Unit, Milan, Italy

  • Fondazione Ca' Granda â€ Ospedale Maggiore Policlinico, Department of Anesthesiology and Intensive Care, Milan, Italy

  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Department of Internal Medicine, Infectious Diseases Unit, Milan, Italy

  • Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico, Radiology - CF Center, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Enoxaparin

  • Enoxaparin sodium

  • Heparin

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved